Skip to content
View in the app

A better way to browse. Learn more.

99NICU

A full-screen app on your home screen with push notifications, badges and more.

To install this app on iOS and iPadOS
  1. Tap the Share icon in Safari
  2. Scroll the menu and tap Add to Home Screen.
  3. Tap Add in the top-right corner.
To install this app on Android
  1. Tap the 3-dot menu (⋮) in the top-right corner of the browser.
  2. Tap Add to Home screen or Install app.
  3. Confirm by tapping Install.

The Codeine and Breastfeeding Controversy (2006-2026): How a Flawed Case Report Reshaped Neonatal Guidelines - and Why The Lancet Retracted It 20 Years Later

Featured Replies

Executive Summary and Clinical Context

For nearly two decades, neonatal and obstetric clinical guidance regarding maternal analgesia was defined by an absolute prohibition: codeine is contraindicated during breastfeeding. Driven by warnings from the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and health agencies worldwide, this dogma originated from a single 2006 case report in The Lancet describing the death of a 13-day-old infant from morphine overdose to which he was allegedly exposed via breast milk. The authors claimed that maternal ultrarapid cytochrome P450 2D6 (CYP2D6) metabolism converted standard postpartum codeine doses into a lethal concentration of morphine, which passed to the infant via breast milk.

In response, clinical practice pivoted away from codeine toward higher-potency opioids such as oxycodone, hydromorphone, and fentanyl. Other mothers were advised to avoid breastfeeding while taking codeine or endured undertreated postpartum pain.

Today, November 21, 2026, The Lancet formally retracted that landmark 2006 paper following an institutional investigation that confirmed scientific data falsification - specifically, the deliberate omission of toxicological and postmortem findings consistent with direct neonatal pill ingestion rather than transmission through breast milk. Below is an elaborate chronological history of this controversy, its pharmacological deconstruction, and the clinical implications for neonatal practice.

Bottom line:

This 20-year-long saga has reshaped postpartum pain management and lactational pharmacology, demonstrating a defensive and conservative approach, which may have been suboptimal by pushing mothers toward stronger opioids. Following its conclusion in a retraction of the seminal "Toronto case", we are reminded that clinical decision-making should not be based on isolated cases, no matter how tragic or outstanding. Such reports may trigger the "fallacy of misleading vividness", goading clinicians into unsubstantiated practices to avoid such remote and improbable outcomes. Moving forward, neonatal and perinatal care must remain anchored in rigorous pharmacokinetic modeling, robust epidemiological cohorts, and evidence-based multimodal analgesia.

** Disclaimer: this post is based on the relevant publications (see reference list in the end) and was compiled and written with the assistance of Google NotebookLM. It was then thoroughly reviewed by myself before posting. Any additions or corrections are welcome. **


Chronological Timeline of Events

2005 ── Infant death (Toronto)
2006 ── Landmark Lancet case published; CPJ column
2007 ── CFP article; FDA Public Health Advisory
2008 ── Bateman et al. critique in Lancet; Motherisk case-control study
2009 ── Willmann PBPK modeling; Motherisk 4-day guidelines
2010 ── Fabricated "Baby Boy Blue" vignette published in Paediatr Child Health
2011 ── Confidential review uncovers concealed 300 ng/mL codeine and stomach pill residue
2012 ── Juurlink cohort (n=7,804 mother-infant pairs) shows no codeine harm
2013 ── Kelly et al. prospective tool (PLoS ONE); EMA/PRAC pediatric restrictions
2015 ── IJOA editorial challenges "numerator of one"
2020 ── Zipursky & Juurlink publish toxicological refutation; CPJ & CFP retract papers
2023 ── BMJ cohort (n=85,675 dyads) and Bateman/Hale editorial confirm relative infant safety
2026 ── New Yorker exposé; 123 CPS case disclaimers; Lancet Expression of Concern (Feb);
        Formal Retraction of Lancet paper (Nov 21)

Detailed Chronological Development

1. The Incident and the Original Report (April 2005 – August 2006)

  • April 2005: In Toronto, Ontario, a healthy, full-term, 12-day-old infant exhibited poor feeding, lethargy, and grey skin, and was pronounced dead on day 13. His mother had taken Tylenol No. 3 (acetaminophen 300 mg, codeine 30 mg, caffeine 15 mg) for episiotomy pain, 2 tablets twice daily, and from the second day onward one tablet every 6 hours. Postmortem blood testing demonstrated a markedly elevated morphine concentration of 70 ng/mL.

  • August 2006: Dr. Gideon Koren (Director of the Motherisk Program at Toronto's Hospital for Sick Children) and colleagues (including Ontario Deputy Chief Coroner Dr. James Cairns) published the case in The Lancet:

2. Regulatory Shockwaves and Practice Shifts (Late 2006 - 2007)

3. Toxicological Debate and Pharmacokinetic Modeling (2008 – 2010)

4. The Confidential Investigation and Epidemiological Studies (2010 - 2015)

5. Toxicological Refutation and Initial Retractions (2020 – 2023)

6. The New Yorker Exposé and Retraction of The Lancet Paper (2026)


Forensic and Pharmacokinetic Comparison

The following table contrasts the incomplete data published in The Lancet (2006) with the full forensic profile established by postmortem toxicology and re-investigation:

Analytical Parameter

As Reported in The Lancet (2006)

Complete Postmortem Findings (Zipursky & Juurlink, 2020)

Neonatal Pharmacological Significance

Postmortem Blood Morphine

70 ng/mL

70 ng/mL

Normal therapeutic analgesic plasma concentrations in neonates receiving IV morphine are 10-15 ng/mL; 70 ng/mL is potentially lethal.

Postmortem Blood Codeine

Not reported (omitted)

300 ng/mL

~50 times higher than peak neonatal levels from breast milk (~2.2 ng/mL); indicates massive direct ingestion of codeine.

Postmortem Blood Acetaminophen

Not reported (omitted)

5.9 µg/mL

Incompatible with milk transfer; acetaminophen has minimal postmortem redistribution.

Gastric Contents

Not reported (omitted)

Curdled white material containing codeine

Direct physical evidence of crushed tablet administration into the stomach.

Maternal Breast Milk Morphine

87 ng/mL (stored day 10)

87 ng/mL

At 87 ng/mL, consuming 1,000 mL/day provides only 87 µg/day of morphine.

Relative Infant Dose (RID) - Morphine

Not calculated

<1.2%

Standard pediatric safety cutoff is <10%. Normal neonatal oral therapeutic dosing is up to 3,200 µg/day.

Renal Function Status

Presumed "immature"

Normal hydration and urine output

Pediatrician documented birth weight recovery and 5 wet diapers the day before death, refuting the anuric accumulation required by PBPK models.


Key Takeaways for Neonatal and NICU Practice

  1. Lactational Opioid Transfer is Naturally Constrained: All opioids transfer into mature breast milk in small quantities. Standard therapeutic maternal doses yield an RID well below the 10% threshold. Fatal neonatal accumulation is highly unlikely via breast milk in a thriving infant with preserved renal clearance. For premature or otherwise ill neonates, an individualized decision-making process and monitoring scheme should be undertaken.

  2. Beware the Substitution of Riskier Alternatives: Replacing codeine with high-potency opioids (oxycodone, hydromorphone, fentanyl) increases maternal dependence liability, diversion hazards, and potential neonatal adverse effects.

  3. Current Standard of Care (Stepwise Multimodal Analgesia): Postpartum pain should be managed with scheduled non-opioids (ibuprofen and acetaminophen) as the foundational tier. If breakthrough opioids are required, short courses (≤3-4 days) should be used. Mothers should be educated to monitor for extreme somnolence in themselves and poor latch, feeding difficulties, or limpness in their infants.


References

  1. Bateman DN, Eddleston M, Sandilands E. Codeine and breastfeeding. Lancet 2008; 372(9639): 625.

  2. Bateman DN, Hale TW. Opioid analgesia for breastfeeding mothers: New study reports reassuring evidence on safety for infants. BMJ 2023; 380: p514.

  3. Canadian Paediatric Society. Society note on 123 papers to add disclaimer. Paediatr Child Health 2026.

  4. Dyer O. Breastfeeding and codeine guidance in doubt after calls for retraction of pivotal Lancet study. BMJ 2026; 392: s498.

  5. European Medicines Agency (EMA) / CMDh. Restrictions on use of codeine for pain relief in children – CMDh endorses PRAC recommendation. 2013.

  6. Ferner RE. Did the drug cause death? Codeine and breastfeeding. Lancet 2008; 372(9639): 606–608.

  7. Halder S, Russell R, Quinlan J. Codeine and breast-feeding mothers. Int J Obstet Anesth 2015; 24(1): 5–7.

  8. Juurlink DN, Gomes T, Guttmann A, et al. Postpartum maternal codeine therapy and the risk of adverse neonatal outcomes: a retrospective cohort study. Clin Toxicol (Phila) 2012; 50(5): 390–395.

  9. Kelly LE, Chaudhry SA, Rieder MJ, et al. A Clinical Tool for Reducing Central Nervous System Depression among Neonates Exposed to Codeine through Breast Milk. PLoS ONE 2013; 8(7): e70073.

  10. Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2006; 368(9536): 704. [RETRACTED]

  11. Madadi P, Koren G, Cairns J, et al. Maternal codeine is not safe for all breast-fed infants. Can Pharm J 2006; 139(6): 56–57. [RETRACTED]

  12. Madadi P, Koren G, Cairns J, et al. Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine. Can Fam Physician 2007; 53(1): 33–35. [RETRACTED]

  13. Madadi P, Chitayat D, Koren G. Codeine and breastfeeding – Authors' reply. Lancet 2008; 372(9639): 626.

  14. Madadi P, Ross CJ, Hayden MR, et al. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin Pharmacol Ther 2009; 85(1): 31–35.

  15. Madadi P, Moretti M, Djokanovic N, et al. Guidelines for maternal codeine use during breastfeeding. Can Fam Physician 2009; 55(11): 1077–1078.

  16. Rieder M, Koren G. Baby boy blue – why is this newborn lethargic? Paediatr Child Health 2010; 15(9): 571–572.

  17. Rieder M. Codeine toxicity via breast Milk: Can this occur and implications for opiate therapy in children. Br J Clin Pharmacol 2026; 92(9): 3012–3016.

  18. Springer Publishing / DailyNurse. Codeine and Breastfeeding: What Clinicians Need to Know After the Lancet Retraction. 2026.

  19. Taub B. Did a Celebrated Researcher Obscure a Baby's Poisoning? The New Yorker (January 26, 2026).

  20. The Editors of The Lancet. Expression of Concern: Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2026; 407(10528): 659.

  21. The Editors of The Lancet. Retraction: Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2026; 408: 1812.

  22. Tsuyuki RT, Pimlott N. Risks of maternal codeine intake in breast-fed infants: A Joint Statement of Retraction from the Canadian Pharmacists Journal and Canadian Family Physician. Can Pharm J (Ott) 2020; 154(1): 7–8 / Can Fam Physician 2020; 66(11): 793–796.

  23. US Food and Drug Administration (FDA). Public Health Advisory: Use of Codeine By Some Breastfeeding Mothers May Lead To Life-Threatening Side Effects In Nursing Babies. 2007.

  24. Willmann S, Edginton AN, Coboeken K, Ahr G, Lippert J. Risk to the breast-fed neonate from codeine treatment to the mother: a quantitative mechanistic modeling study. Clin Pharmacol Ther 2009; 86(6): 634–643.

  25. Zipursky J, Juurlink DN. The Implausibility of Neonatal Opioid Toxicity from Breastfeeding. Clin Pharmacol Ther 2020; 108(5): 964–970.

  26. Zipursky JS, Gomes T, Everett K, et al. Maternal opioid treatment after delivery and risk of adverse infant outcomes: population based cohort study. BMJ 2023; 380: e074005.

To read the comments in this discussion, please log in or register. It's free and open to neonatal care professionals worldwide!

Account

Navigation

Search

Search

Configure browser push notifications

Chrome (Android)
  1. Tap the lock icon next to the address bar.
  2. Tap Permissions → Notifications.
  3. Adjust your preference.
Chrome (Desktop)
  1. Click the padlock icon in the address bar.
  2. Select Site settings.
  3. Find Notifications and adjust your preference.